BT-50 Main target antigen for atypical pANCA for use in diagnostic tests

Scientists at the University of Bonn, Germany, have identified the main target antigen for the atypical antineutrophil

cytoplasmic antibodies pANCA in autoimmune liver disorders and chronic inflammatory bowel diseases. BT-50 can be produced by recombinant means and used for the quantification of atypical pANCA in serum probes.

Further Information: PDF

PROvendis GmbH
Phone: +49 (0)208/94105 0

Contact
Dipl.-Ing. Alfred Schillert

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All latest news from the category: Technology Offerings

Back to home

Comments (0)

Write a comment

Newest articles

Zap Energy achieves 37-million-degree temperatures in a compact device

New publication reports record electron temperatures for a small-scale, sheared-flow-stabilized Z-pinch fusion device. In the nine decades since humans first produced fusion reactions, only a few fusion technologies have demonstrated…

Innovative microscopy demystifies metabolism of Alzheimer’s

Researchers at UC San Diego have deployed state-of-the art imaging techniques to discover the metabolism driving Alzheimer’s disease; results suggest new treatment strategies. Alzheimer’s disease causes significant problems with memory,…

A cause of immunodeficiency identified

After stroke and heart attack: Every year, between 250,000 and 300,000 people in Germany suffer from a stroke or heart attack. These patients suffer immune disturbances and are very frequently…

Partners & Sponsors